Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Oncotarget - 22 Sept 2015

Barrett Michael T, Anderson Karen S, Lenkiewicz Elizabeth, Andreozzi Mariacarla, Cunliffe Heather E, Klassen Christine L, Dueck Amylou C, McCullough Ann E, Reddy Srikanth K, Ramanathan Ramesh K, Northfelt Donald W, Pockaj Barbara A

Abstract excerpt

We used DNA content flow cytometry followed by oligonucleotide array based comparative genomic hybridization to survey the genomes of 326 tumors, including 41 untreated surgically resected triple negative breast cancers (TNBC). A high level (log2ratio ≥ 1) 9p24 amplicon was found in TNBC (12/41),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 9

Share to Comparative Genomic Hybridization

Share to Disease-Free Survival

Share to Glioblastoma

Share to Janus Kinase 2

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26317899
DOI: 10.18632/oncotarget.4494
PMCID: PMC4694916

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26317899-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.PMID 26317899Read ↗

JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast CancerSemantic proximity Read ↗

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.Semantic proximity Read ↗

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.Semantic proximity Read ↗

Comprehensive genomic profiling of malignant phyllodes tumors of the breast.Semantic proximity Read ↗

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaSemantic proximity Read ↗

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.Semantic proximity Read ↗

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.Semantic proximity Read ↗

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceSemantic proximity Read ↗

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted TherapiesSemantic proximity Read ↗

Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.Semantic proximity Read ↗

Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancerSemantic proximity Read ↗

<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.